A similar observation from Vivero et al. [25] suggested that MTs can be distinguished by the presence of YAP1–MAML2 fusions and the absence of GTF2I mutations in contrast to Type A and AB thymomas; therefore, they represent a distinct and clinically benign entity [24]. The gene discussed is MAML2; the disease is thymoma.